Ticker: PCVX

Vaxcyte

Biotech Healthcare Biotechnology

Price 59.57

Reco Sell Potential 42 Risk 70 Updated 2026-10-26

Official website

Forecast impact

neutral

Target +101.9% target fill 49.5%

Reaction D5 -1.76% · D10 -9.33%

Impact Potential 0 · Risk 0 valid until 2026-11-04

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell

Description

Company and Business Model

Vaxcyte, Inc. is a biotechnology company focused on developing innovative vaccines to address infectious diseases. Its core products include a pipeline of vaccine candidates targeting various pathogens, with a primary emphasis on pneumococcal disease. The company operates within the healthcare sector, primarily generating revenue through research and development activities and potential future product sales.

Investment Profile

The investment profile of Vaxcyte is more aligned with growth investors, given its focus on developing new vaccine technologies and the potential for significant future revenue from successful product launches. The stock may appeal to those with a medium to long-term investment horizon, as the company is still in the development phase. Liquidity is moderate, suitable for investors with basic to advanced experience in the biotech sector.

Category: Biotech Sector: Healthcare Industry: Biotechnology Investment style: Growth Horizon: Medium-term Company type: Niche Player

Fundamental metrics (experimental) Updated: 2026-10-24

EPS (TTM) — earnings per share for the last 12 months, $: -7.64
EPS surprise: 4.4%
20d volatility: 7.9%

AI recommendation changes

Date	Before	After	Reason
2026-10-19	Hold	Sell	Weak fundamentals and high volatility raise concerns.
2026-10-07	Sell	Hold	Weak fundamentals and high volatility raise concerns.
2026-09-07	Hold	Sell	Weak fundamentals and high risk limit upside potential.
2026-08-25	Sell	Hold	Weak fundamentals, high risk, uncertain market conditions.
2026-08-17	Hold	Sell	Weak fundamentals and high risk limit upside potential.
2026-08-10	Sell	Hold	Weak fundamentals and high risk limit upside potential.
2026-07-09	Hold	Sell	Weak fundamentals and negative momentum raise significant concerns.
2026-06-27	Sell	Hold	Weak fundamentals and high risk limit upside potential.
2026-06-03	Hold	Sell	scenario_deterioration
2026-05-28	Sell	Hold	Weak fundamentals and negative momentum raise concerns.
2026-05-20	Hold	Sell	scenario_deterioration
2026-05-08	—	Hold	Weak fundamentals and negative momentum raise significant concerns.
2026-05-08	Hold	Hold	Компания демонстрирует значительное снижение цен на акции в краткосрочной перспективе и отрицательный EPS, что указывает на высокие риски и неопределенность в будущем.
2026-02-10	Buy	Hold	Компания демонстрирует сильный рост за последние месяцы, но отрицательный EPS и высокая волатильность указывают на риски. Рекомендуется удерживать акции до получения более ясных сигналов о финансовом состоянии.
2026-01-30	Hold	Buy	Компания демонстрирует значительный рост за последние 120 дней, что указывает на позитивные ожидания. Однако высокая волатильность и отсутствие данных по EPS и выручке могут представлять определенные риски.
2026-01-29	Buy	Hold	Компания показывает значительный рост за последние 120 дней, однако недавнее падение на 5.48% и отсутствие данных по EPS и выручке создают неопределенность. Рекомендуется удерживать акции до получения более ясных финансо

Analyst forecasts

Date	Analyst	Action	Target	Price Then
2026-10-12	Cantor Fitzgerald	Update	— → 120	71.38
2026-10-05	Needham	Target Raised	110 → 122	72.3
2026-10-05	Guggenheim	Target Raised	— → 125	56.48
2026-02-25	BTIG	Target Raised	— → 89	63.04
2025-11-19	Leerink Partners	Target Raised	— → 77	49.53

News Page 1 of 1

Nothing yet